UniProtKB/SwissProt variant VAR

Variant information

Variant position:

537

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:

Disease [Disclaimer]

The variants are classified into three categories: Disease, Polymorphism and Unclassified.

Disease: Variants implicated in disease according to literature reports.
Polymorphism: Variants not reported to be implicated in disease.
Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:

From Glycine (G) to Arginine (R) at position 537 (G537R, p.Gly537Arg).

Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:

Change from glycine (G) to large size and basic (R)

The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:

-2

The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page

Involvement in disease:

Erythrocytosis, familial, 4 (ECYT4) [MIM:611783]: An autosomal dominant disorder characterized by increased serum red blood cell mass, elevated serum hemoglobin and hematocrit, and normal platelet and leukocyte counts. {ECO:0000269|PubMed:18184961, ECO:0000269|PubMed:18378852, ECO:0000269|PubMed:19208626, ECO:0000269|PubMed:22367913}. Note=The disease is caused by mutations affecting the gene represented in this entry.

The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:

In ECYT4; impairs interaction with EGLN1 and VHL.

Any additional useful information about the variant.

Other resources:

Links to websites of interest for the variant.

Variant rs137853036 [ dbSNP | Ensembl ]

Sequence information

Variant position:

537

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:

870

The length of the canonical sequence.

Location on the sequence:

TQTDFNELDLETLAPYIPMD G EDFQLSPICPEERLLAENPQ

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         TQTDFNELDLETLAPYIPMDGEDFQLSPICPEERLLAENPQ

Mouse                         TQTDFSELDLETLAPYIPMDGEDFQLSPICPEEPLMPESPQ

Rat                           TQTDFNELDLETLAPYIPMDGEDFQLSPICPEEPLVPESPQ

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 870	Endothelial PAS domain-containing protein 1
Region	496 – 542	NTAD
Modified residue	531 – 531	4-hydroxyproline

Literature citations

Erythrocytosis-associated HIF-2alpha mutations demonstrate a critical role for residues C-terminal to the hydroxylacceptor proline.
Furlow P.W.; Percy M.J.; Sutherland S.; Bierl C.; McMullin M.F.; Master S.R.; Lappin T.R.; Lee F.S.;
J. Biol. Chem. 284:9050-9058(2009)
Cited for: INTERACTION WITH EGLN1 AND VHL; VARIANT ECYT4 LEU-534; CHARACTERIZATION OF VARIANTS ECYT4 LEU-534; VAL-535 AND ARG-537;

Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis.
Percy M.J.; Beer P.A.; Campbell G.; Dekker A.W.; Green A.R.; Oscier D.; Rainey M.G.; van Wijk R.; Wood M.; Lappin T.R.; McMullin M.F.; Lee F.S.;
Blood 111:5400-5402(2008)
Cited for: VARIANTS ECYT4 VAL-535 AND ARG-537;

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q99814: Variant p.Gly537Arg